See every side of every news story
Published loading...Updated

AIM Vaccine submits mRNA RSV vaccine for FDA clinical trials

Summary by News Medical
AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to the U.S. Food and Drug Administration (FDA).

2 Articles

All
Left
Center
1
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Johns Hopkins University broke the news in Baltimore, United States on Monday, February 10, 2025.
Sources are mostly out of (0)